Implementing Maximum Fair Price Without Hurting Pharmacies
The Inflation Reduction Act (IRA) introduced reforms addressing escalating drug costs in the US, including a new negotiating power for Medicare.1 Under this new authority, the Centers for...
Verdant’s projects examine how federal policies, market structure, and drug-level economics shape the pharmaceutical market and supply chain. Our portfolio includes grant-funded research, advisory engagements, and expert testimony in pharmaceutical matters.
Pharmaceutical Innovation and the Inflation Reduction Act: 2023 in Review
Despite assertions by industry stakeholders that this new policy would stifle innovation, we found few actions by these companies through the first half of 2023 that could be...
How Medicare Negotiations Can Avoid Manufacturers’ Loopholes and Save Consumers Money
A year after the passage of the Inflation Reduction Act (IRA), Medicare negotiation reached its first major milestone, with the federal government and pharmaceutical manufacturers entering into agreements...
Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors
By inflating the amount paid to pharmacies, PBMs make patients pay more because patient cost sharing is based on point-of-sale reimbursement. The PBMs recover significant portions of point-of-sale...
Medicare Negotiation And Innovation: A Response To O’Brien And Co-Authors
In a November Health Affairs Forefront article, John O’Brien, James Motyka and Julie Patterson argued that Medicare price negotiation under the Inflation Reduction Act (IRA) could delay the...
Lead with Evidence
Partner with Verdant for rigorous, objective economic analysis.